Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers
This study has been terminated.
(Low recruitment rate)
Sponsor:
ApoPharma
Information provided by:
ApoPharma
ClinicalTrials.gov Identifier:
NCT00387101
First received: October 10, 2006
Last updated: April 30, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the safety and efficacy of Dermal-LSR plus Standard of Care (SOC) for the treatment of diabetic foot ulcers (DFU)in comparison to the treatment to SOC alone.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Foot Ulcer |
Device: Dermal - Living Skin Replacement (Dermal - LSR) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pivotal Study to Evaluate the Efficacy and Safety of Dermal-Living Skin Replacement (Dermal-LSR) in the Treatment of Chronic Diabetic Foot Ulcers |
Resource links provided by NLM:
Further study details as provided by ApoPharma:
Primary Outcome Measures:
- To determine the efficacy and safety of Dermal-LSR plus Standard of Care (SOC) for the treatment of chronic diabetic foot ulcers in comparison to treatment with SOC alone.
| Estimated Enrollment: | 288 |
| Study Start Date: | February 2006 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
The study is a pivotal, prospective, randomized, controlled, open-label, multi-center study that will evaluate the effectiveness and safety of topically applied Dermal-LSR in chronic DFUs.
Eligibility| Ages Eligible for Study: | 18 Years to 84 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Has signed a written informed consent prior to the first study intervention
- Is at least 18 and <85 years of age
- Has one or more diabetic foot ulcers on the target limb, with only one marked for the study (target ulcer). It must have the following characteristics:Plantar; Grade 2 per Curative Health Services Classification; Non-infected; Neuropathic; Non-malignant; At least 1.0-25cm^2 post-debridement; Present for at least 6 weeks
- Has Type I or II Diabetes Mellitus with an HBA1c between 6-10%
- Has a maximum fasting blood glucose level of 13.8 mmol/L
- An ankle-brachial systolic pressure index between 0.7 and 1.3
- If female and of childbearing potential has a negative serum pregnancy test and is neither breastfeeding or intending to become pregnant during the study
- Able and willing to attend the scheduled visits and comply with study procedures.
Exclusion Criteria:
- Known or suspected disease of the immune system
- Active or untreated malignancy or active, uncontrolled connective tissue disease
- Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before enrollment
- Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement
- Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb < 4 weeks prior to enrollment
- Active febrile illness
- AST, ALT, ALP >3x the normal upper limit
- Serum Creatinine >2x the normal upper limit
- Osteomyelitis
- Active Charcot
- Use of any topical treatments other than SOC (standard of care)at the time of enrollment
- Enrollment in any investigational clinical trial within 30 days of the screening visit
- Known or suspected hypersensitivity to any study product components
- Recent or current history of alcohol or drug abuse
- Any condition, which in the opinion of the Investigator, would interfere with the evaluation of the study product or poses a health risk to the subject
- All site personnel directly affiliated with this study and their immediate families
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00387101
Locations
| United States, Arizona | |
| Southern Arizona Veterans Administration Health Care System, 3601 S. 6th Avenue (2-112) | |
| Tuscon, Arizona, United States, 85723 | |
| United States, California | |
| Veterans Affairs Northern Health Care System, Sacramento VA Medical Center at Mather | |
| Mather, California, United States, 95655 | |
| San Diego Research Center 4452 Park Boulevard Suite 210, San Diego | |
| San Diego, California, United States, 92116 | |
| United States, Florida | |
| Doctors Research Network | |
| South Miami, Florida, United States, 33143 | |
| United States, Illinois | |
| Weil Foot and Ankle Institute | |
| Des Plaines, Illinois, United States, 60016 | |
| Hines VA Hospital | |
| Hines, Illinois, United States, 60141 | |
| National Center for Lower Limb Preservation | |
| Niles, Illinois, United States, 60714 | |
| United States, Massachusetts | |
| Foot Care Vascular and Endovascular Specialists of Boston Medical Center | |
| Boston, Massachusetts, United States, 02118 | |
| Joslin-Beth Israel Deaconess Foot Center, Division of Podiatry, 185 Pilgrim Road | |
| Boston, Massachusetts, United States, 02215 | |
| United States, New York | |
| North Shore Diabetic and Endocrine Associates | |
| New Hyde Park, New York, United States, 11042 | |
| United States, Ohio | |
| The Learner Research Centre, Department of Orthopaedic Surgery. The Cleveland Clinic Foundation, 9500 Euclid Ave. A40 | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Pennsylvania | |
| Center for Advanced Wound Care | |
| Reading, Pennsylvania, United States, 19601 | |
Sponsors and Collaborators
ApoPharma
Investigators
| Principal Investigator: | Jason R Hanft, DPM, FAC FAS | Doctors Research Network, 7000 SW 62nd Avenue, Suite 310, South Miami, FL 33143 |
| Principal Investigator: | Hau Pham, DPM | Foot Care Vascular and Endovascular Specialists of Boston Medical Center, 732 Harrison Ave., 2nd Floor, Boston, MA 02118 |
| Principal Investigator: | Rodney Stuck, DPM | Hines VA Hospital, 5th and Roosevelt Rd., Building 200, 5th Floor, Room 501, Hines, IL 60141 |
| Principal Investigator: | Vickie Driver, DPM | National Center for Lower Limb Preservation, 8816 Dempster Street, Niles, Il 60714 |
| Principal Investigator: | Zevi Isseroff, DPM | North Shore Diabetic and Endocrine Associates, 3003 New Hyde Park Road Suite 201, New Hyde Park, NY, 11042 |
| Principal Investigator: | Lowell Weil, Jr., DPM, MBA, FAC FAS | Weil Foot and Ankle Institute, 1455 Golf Rd., Suite 110, Golf-River Professional Building, Des Plaines, IL 60016 |
| Principal Investigator: | Michal Drews | SPSK nr 2 im. H. Święcickiego AM Oddział Kliniczny Chirurgii Ogólnej Gastroenterologicznej i Endokrynologicznej ul. Przybyszewskiego 49 |
| Principal Investigator: | Henryk Komon | Centrum Medyczno-Diagnostyczne Sp. z o.o. ul. Piłsudskiego 49 08-110 Siedlce Poland |
| Principal Investigator: | Krystyna Pilarska | SPWSZ w Szczecinie Klinika Endokrynologii, NadciśnieniaTętniczego i Chorób Przemiany Materii PAM ul. Arkońska 4 71-455 Szczecin |
| Principal Investigator: | Malgorzata Wilczynska | NZOZ Centrum Opieki Diabetologiczno-Endokrynologicznej ul. Karola Miarki 6 50-306 Wrocław Poland |
| Principal Investigator: | Joseph Cavorsi, M.D. | Center for Advanced Wound Care 640 Walnut St., Suite 302 Reading, PA 19601 |
| Principal Investigator: | Roslyn R Isseroff, M.D. | Veterans Affairs Northern Health Care System |
| Principal Investigator: | Georgeanne Botek, DPM | The Learner Research Centre, Department of Orthopaedic Surgery. The Cleveland Clinic Foundation, 9500 Euclid Ave. A40, Cleveland, OH 44195, |
| Principal Investigator: | Adam Landsman, DPM, PhD | Joslin-Beth Israel Deaconess Foot Center, Division of Podiatry, 185 Pilgrim Road, Boston, MA 02215 |
| Principal Investigator: | Jodi Walters, DPM | Southern Arizona Veterans Administration Health Care System, 3601 S. 6th Avenue (2-112), Tucson, AZ 85723 |
| Principal Investigator: | Martin Taubman, DPM | San Diego Research Center 4452 Park Boulevard Suite 210, San Diego, CA 92116 |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00387101 History of Changes |
| Other Study ID Numbers: | RS03-2004 |
| Study First Received: | October 10, 2006 |
| Last Updated: | April 30, 2008 |
| Health Authority: | United States: Food and Drug Administration European Union: European Medicines Agency Canada: Health Canada |
Keywords provided by ApoPharma:
|
Diabetic Foot Ulcer Diabetes Mellitus Debridement Dermal-LSR Standard of Care |
Additional relevant MeSH terms:
|
Foot Ulcer Diabetic Foot Foot Diseases Ulcer Pathologic Processes Skin Diseases Leg Ulcer Skin Ulcer |
Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies |
ClinicalTrials.gov processed this record on May 22, 2013